Navigation Links
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Date:6/8/2009

of treatment with bcr-abl inhibitors, and patients with t(4;11) translocations. Side effects were observed primarily in the first 24 to 48 hours with transient pyrexia and lympho-/leukopenia being the most frequent adverse events.

"Blinatumomab is one of the most active agents the GMALL has tested in the adult ALL consolidation setting," said Dr. Ralf Bargou, principal investigator of the trial. "We are excited about the significant activity of blinatumomab in ALL and the favorable safety profile observed in this study. These results are particularly important for these patients who are in a disease stage with extremely poor prognosis and for which we lack treatment options except for patients eligible for allogenic stem cell transplantations."

"The ALL interim data showing an MRD response rate above 80% significantly exceeds the rate which was considered to be clinically meaningful and was set as the hurdle for the achievement of the primary end point," said Micromet's Senior Vice President and Chief Medical Officer, Carsten Reinhardt, M.D. "We are now looking forward to discussing a pivotal ALL program with the regulatory authorities later this year."

    (1) Topp, M.S. et al (2009). Blinatumomab (anti-CD19 BiTE(R)) for targeted
        therapy of minimal residual disease (MRD) in patients with B precursor
        acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II
        study. 14th Congress of the EHA 2009, abstract no. 482


Webcast/Conference Call

Micromet will host a webcast/conference call this morning from 9:00 am to 11:00 am U.S. Eastern time to discuss the blinatumomab data presented at the 14th Congress of the European Hematology Association. The webcast will be available on the company's website at www.micromet-inc.com. To participate in the conference call, dial 866
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
2. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
3. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new report, "Germany ... market data on the Germany Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... SANTA MONICA, Calif. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... who is at the White House today for National ... Proposition 46 that consumer advocates released today. Consumer advocates ... woman who spoke out after losing her ... later discovering that the doctor had a history of ...
(Date:9/17/2014)... , Sept. 17, 2014  Decision ... colitis (CD/UC) patients eligible for biologic therapy, ... a biologic. Surveyed gastroenterologists cite patients, discomfort ... for low penetration rates, followed by cost-related ... UC patients receiving biologics, Janssen Biotech,s Remicade ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
... OncoSec Medical Incorporated (OTCBB:ONCS), which is developing ... to treat solid tumor cancers, today announced that ... and Lakeland Comprehensive Cancer Center in Lakeland, FL ... are screening patients for the Phase II metastatic ...
... International, Inc. (NASDAQ: BDSI ) announced that ... of further litigation in the patent infringement lawsuit previously ... that the case would be stayed pending resolution by ... proceedings and follows the recent rejection by the USPTO ...
Cached Medicine Technology:OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 2Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 3
(Date:9/18/2014)... September 18, 2014 Specialty Teleradiology ... Westlake, OH, announces that they have achieved Meaningful ... a Complete Certified Ambulatory EHR-certified system developed by ... Teleradiology had a non MU compliant PACS and ... business grew from a niche in oncology to ...
(Date:9/17/2014)... 18, 2014 Recently, BambooIndustry.com, an outstanding company ... bamboo floorings . There are more than 1000 items ... launched a big promotion for these useful items. Each of ... % off. , “We are very proud to unveil ... say, all these items are made with natural materials by ...
(Date:9/17/2014)... IntimateRider, an inventor of classy sexual enhancement ... it has entered into a dealership agreement with new ... reason for the deal is the fact that All ... its sales potential, representatives at the mobility products firm ... latest products on the market both nationally and internationally." ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 US medical ... tons of medical waste in 2014. Due to public ... in landfills along with municipal solid waste. An increasing ... regulated medical waste (RMW). This includes disposable items that ... potentially infectious materials. As a result of increased regulation, ...
(Date:9/17/2014)... 2014 As kinship care continues to ... cannot live with their parents, emphasis on kinship care ... enhance services and supports for kinship caregivers and families. ... Kinship Care Conference is being held this week in ... practice, policy, program and service development for kinship caregivers, ...
Breaking Medicine News(10 mins):Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2
... 7 Perot Systems,Corporation (NYSE: PER ) ... it acquired in August 2007, will fully transition ... toward full,integration. Perot Systems will now refer to ... its ability to access the global information,technology provider,s ...
... announced today that Immediate Past President and public,health leader ... home outside,East Lansing, Michigan. He was diagnosed with pancreatic ... served as the 162nd,president of the AMA from June ... on,preventive medicine and had been a longtime public health ...
... by a tumor or injury carry a severe psychological and ... in plastic surgery. Helmut Fischer and Wolfgang Gubisch present the ... of Deutsches rzteblatt International ( Dtsch Arztebl Int ... a woman who had had a tumor removed from the ...
... to bone marrow transplantation pioneered in part by a ... to be the only safe and effective cure for ... Lakshmanan Krishnamurti, MD, a pediatric hematologist/oncologist at Children,s Hospital, ... relies on reduced-intensity conditioning (RIC). RIC regimens are less ...
... Allscripts-Misys Healthcare,Solutions, Inc. (formerly named Allscripts Healthcare Solutions, ... ("Allscripts") and,headquartered in Chicago, Illinois announced today its ... Convertible Senior Debentures due 2024 (the,"Debentures") at a ... to 100% of the principal amount of the ...
... - Nearly 700 health plans evaluated based on ... 7 U.S. News Media Group and The,National ... fourth,annual edition of America,s Best Health Plans on ... millions of Americans prepare to,select their healthcare coverage, ...
Cached Medicine News:Health News:Perot Systems Announces Name Change of JJWild 2Health News:Perot Systems Announces Name Change of JJWild 3Health News:AMA Immediate Past President Ron Davis Loses Battle With Cancer, Leaves Enduring AMA and Public Health Legacy 2Health News:AMA Immediate Past President Ron Davis Loses Battle With Cancer, Leaves Enduring AMA and Public Health Legacy 3Health News:Children's Hospital study demonstrates how bone marrow transplant can cure sickle cell disease 2Health News:Allscripts Announces Notice of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 2Health News:Allscripts Announces Notice of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 3Health News:Allscripts Announces Notice of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 4Health News:U.S. News Media Group and NCQA Release 2008 Rankings for America's Best Health Plans 2Health News:U.S. News Media Group and NCQA Release 2008 Rankings for America's Best Health Plans 3